Skip to Content
Merck
All Photos(1)

Documents

DUO82064

Sigma-Aldrich

Duolink® In Situ Microplate Nuclear Stain, Anti-Fade

Synonym(s):

in situ Proximity Ligation Assay reagent, Protein Protein Interaction Assay reagent

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352200
NACRES:
NA.32

product line

Duolink®

Quality Level

200

technique(s)

proximity ligation assay: suitable

fluorescence

λex 360 nm; λem 460 nm

suitability

suitable for fluorescence-detection automated sequencing
suitable for microtiter plates

shipped in

dry ice

storage temp.

−20°C

Related Categories

Application

Duolink®proximity ligation assay(PLA®) allows for endogenous detection of protein interactions, post translational modifications, and protein expression levels at the single molecule level in fixed cells and tissue samples.

Use the Multiwell Plates modifications to the Duolink® In Situ Fluorescence Protocol to run an experiment with this product. A set of short instructions can also be used.

Visit our Duolink® PLA Resource Center for information on how to run a Duolink® experiment, applications, troubleshooting, and more.

To perform a complete Duolink® PLA in situ experiment you will need two primary antibodies (PLA, IHC, ICC or IF validated) that recognize two target epitopes. Other necessary reagents include a pair of PLA probes from different species (one PLUS and one MINUS), detection reagents, wash buffers, and mounting medium. Note that the primary antibodies must come from the same species as the Duolink® PLA probes. Analysis is carried out using standard immunofluorescence assay equipment.
Specificity
Duolink® In Situ Microplate Nuclear Stain and Anti-Fade are intended to be used after staining cells with Duolink® In Situ in microtiter plates. See the datasheet for more information.

Application Note
Two primary antibodies raised in different species are needed. Test your primary antibodies (IgG-class, mono- or polyclonal) in a standard immunofluorescence (IF), immunohistochemistry (IHC) or immunocytochemistry (ICC) assay to determine the optimal fixation, blocking, and titer conditions. Duolink® in situ reagents are suitable for use on fixed cells, cytospin cells, cells grown on slide, formalin-fixed, paraffin embedded (FFPE), or tissue (fresh or frozen). No minimum number of cells is required.

Let us do the work for you, learn more about our Custom Service Program to accelerate your Duolink® projects

View full Duolink® product list

Features and Benefits

  • No overexpression or genetic manipulation required
  • High specificity (fewer false positives)
  • Single molecule sensitivity due to rolling circle amplification
  • Relative quantification possible
  • No special equipment needed
  • Quicker and simpler than FRET
  • Increased accuracy compared to co-IP
  • Publication-ready results

Legal Information

Duolink is a registered trademark of Merck KGaA, Darmstadt, Germany
PLA is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H317 - H412

Hazard Classifications

Aquatic Chronic 3 - Skin Sens. 1

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Charles Lu et al.
PloS one, 7(4), e34833-e34833 (2012-05-05)
Tumor suppressor gene TUSC2/FUS1 (TUSC2) is frequently inactivated early in lung cancer development. TUSC2 mediates apoptosis in cancer cells but not normal cells by upregulation of the intrinsic apoptotic pathway. No drug strategies currently exist targeting loss-of-function genetic abnormalities. We
Jeffrey J Raizer et al.
Cancer, 116(22), 5297-5305 (2010-07-29)
The authors evaluated a 3-week schedule of bevacizumab in patients with recurrent high-grade glioma (HGG). Patients received bevacizumab 15 mg/kg every 3 weeks and were evaluated every 6 weeks until tumor progression. Tissue correlates were used to quantify tumor content
Jaclyn J Renfrow et al.
Neuro-oncology, 13(8), 880-885 (2011-07-30)
We present a novel methodology combining traditional fluorescent in situ hybridization with an in situ protein detection technology called proximity ligation assay. This method has potential to perform a detailed analysis of the relationship between gene status and corresponding protein
Thomas W Bonagura et al.
Endocrinology, 153(6), 2897-2906 (2012-04-13)
We previously showed that advancing the increase in estradiol levels from the second to the first third of baboon pregnancy suppressed placental extravillous trophoblast (EVT) invasion and remodeling of the uterine spiral arteries. Cell culture studies show that vascular endothelial
Yukiko Hasumi et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(44), 18722-18727 (2009-10-24)
Germline mutations in the BHD/FLCN tumor suppressor gene predispose patients to develop renal tumors in the hamartoma syndrome, Birt-Hogg-Dubé (BHD). BHD encodes folliculin, a protein with unknown function that may interact with the energy- and nutrient-sensing AMPK-mTOR signaling pathways. To
View All Related Papers

Articles

Duolink® References

Find Duolink references based on the type of method used, post translational modification detected, and research focus.

Protocols

Duolink® PLA Multicolor Detection Protocol

Duolink® PLA Multicolor Detection Protocol

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service